AXIONLead platform · Oncology
Selective extracorporeal blood purification
A continuous, closed-loop therapy designed to remove disease-causing targets from blood while sparing healthy tissue. Proprietary ROS generation neutralises circulating tumour cells and bloodborne viruses, and amplifies the body's natural anti-tumour response.
Dialysis-like closed-loop therapy that activates focused Reactive Oxygen Species to neutralise circulating tumour cells and bloodborne pathogens — without systemic chemotherapy toxicity.
- NHS Phase I/II trial approved; sponsor and trial number assigned
- Pre-clinical programme successfully completed
- Targets the seed of metastasis, not just late-stage disease
- Outpatient procedure designed to complement standard of care
Trial design
NHS sponsorship, oversight and governance. Primary endpoints: safety and tolerability. Secondary endpoints: early efficacy signals, viral clearance and immune activation. An outpatient procedure with no drug therapy, designed to complement standard of care.
Potential applications
Oncology · Sepsis · Malaria · Hepatitis B & C · Bloodborne pathogens · Autoimmune disorders · Future blood purification therapies
- 01
Blood withdrawn
Whole blood is drawn from the patient into a closed circuit.
- 02
Enters Axion unit
Blood circulates continuously through the Axion therapeutic cartridge.
- 03
Targeted removal
Circulating tumour cells, bloodborne pathogens, harmful proteins and inflammatory mediators.
- 04
Blood returned
Treated blood is safely returned through the closed loop.
- 05
Cycle repeats
Continuous therapy until the desired therapeutic endpoint is reached.